Law Firms Urge Telix Investors as Jan. 9 Lead-Plaintiff Deadline Nears

Overview

• Rosen Law Firm, Faruqi & Faruqi, and Hagens Berman issued reminders for Telix investors to move for lead-plaintiff status by January 9, 2026.
• The putative class covers purchases of Telix securities between February 21, 2025 and August 28, 2025.
• The complaint alleges Telix overstated progress on prostate cancer therapeutic candidates and the quality and compliance of third‑party manufacturing partners.
• Telix disclosed on July 22, 2025 that it received an SEC subpoena regarding disclosures on prostate therapeutics, after which the complaint says ADSs fell more than 13% over two sessions.
• On August 28, 2025 Telix reported an FDA Complete Response Letter for TLX250‑CDx citing CMC deficiencies and Form 483s at two third‑party sites, followed by a more than 21% ADS decline according to the complaint, and no class has yet been certified.